StockNews.AI
LQDA
StockNews.AI
160 days

Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025

1. Liquidia will report full year 2024 results on March 19, 2025. 2. The company focuses on innovative therapies for rare cardiopulmonary diseases. 3. Lead candidate YUTREPIA™ targets pulmonary arterial hypertension and related conditions. 4. Liquidia is also developing L606, a sustained-release form of treprostinil.

Earnings
+0.94%Current Return
VS
-0.4%S&P 500
$13.903/12 08:05 AM EDTEvent Start
$14.0303/13 02:41 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Bullish?

Upcoming financial results may show growth potential and investor confidence. Historical positive earnings announcements have led to significant stock price increases.

How important is it?

The earnings report will provide insights into Liquidia’s financial health and future projections, impacting investor decisions significantly.

Why Short Term?

The market often reacts quickly to earnings reports. Similar companies see immediate impacts within days of announcements.

Related Companies

CNSTVRTXAMGN
MORRISVILLE, N.C., March 12, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its full year 2024 financial results on Wednesday, March 19, 2025. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The live webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location. About Liquidia CorporationLiquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of Liquidia’s lead candidate, YUTREPIA™ (treprostinil) inhalation powder, an investigational drug for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).  The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com. Contact Information Investors:Jason AdairChief Business Officer919.328.4350jason.adair@liquidia.com Media: Patrick WallaceDirector, Corporate Communications919.328.4383patrick.wallace@liquidia.com

Related News